Disparities in screening and treatment of cardiovascular diseases in patients with mental disorders across the world : systematic review and meta-analysis of 47 observational studies

Objective: This study used meta-analysis to assess disparities in cardiovascular disease (CVD) screening and treatment in people with mental disorders, a group that has elevated CVD incidence and mortality. Methods: The authors searched PubMed and PsycInfo through July 31, 2020, and conducted a random-effect meta-analysis of observational studies comparing CVD screening and treatment in people with and without mental disorders. The primary outcome was odds ratios for CVD screening and treatment. Sensitivity analyses on screening and treatment separately and on specific procedures, subgroup analyses by country, and by controlling for confounding by indication, as well as meta-regressions, were also run, and publication bias and quality were assessed. Results: Forty-seven studies (N524,400,452 patients, of whom 1,283,602 had mental disorders) from North America (k526), Europe (k516), Asia (k54), and Australia (k51) were meta-analyzed. Lower rates of screening or treatment in patients with mental disorders emerged for any CVD (k547, odds ratio50.773, 95% CI50.742, 0.804), coronary artery disease (k534, odds ratio50.734, 95% CI50.690, 0.781), cerebrovascular disease (k58, odds ratio50.810, 95% CI50.779, 0.842), and other mixed CVDs (k511, odds ratio50.839, 95% CI50.761, 0.924). Significant disparities emerged for any screening, any intervention, catheterization or revascularization in coronary artery disease, intravenous thrombolysis for stroke, and treatment with any and with specific medications for CVD across all mental disorders (except for CVD medications in mood disorders). Disparities were largest for schizophrenia, and they differed across countries. Median study quality was high (Newcastle-Ottawa Scale score, 8); higher-quality studies found larger disparities, and publication bias did not affect results. Conclusions: People with mental disorders, and those with schizophrenia in particular, receive less screening and lower-quality treatment for CVD. It is of paramount importance to address underprescribing of CVD medications and underutilization of diagnostic and therapeutic procedures across all mental disorders.